Broad-spectrum coverage.

Don’t use it irresponsibly. This Flatiron retrospective cohort study of almost 5700 patients with NSCLC suggests that those receiving broad-based genomic sequencing enjoyed no improvement in survival compared to those getting EGFR / ALK testing alone, probably because <5% of broad-based tests were used to inform treatment decisions. | Presley, JAMA 2018